
    
      The goal of this study is to determine if preoperative dosing and sustained administration of
      pan-genotypic DAA therapy after kidney transplantation prevents the transmission of hepatitis
      C virus (HCV) infection from an HCV positive donor kidney to an HCV na√Øve recipient.
    
  